Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy
Open Access
- 12 April 2024
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (6) , 108324
Abstract
No abstract availableKeywords
Funding Information
- FRQS
This publication has 36 references indexed in Scilit:
- Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?The Breast, 2022
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerAnnals of Oncology, 2022
- Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioningBreast Cancer Research and Treatment, 2021
- Clinical practice guidelines for BRCA1 and BRCA2 genetic testingEuropean Journal of Cancer, 2021
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Evaluation of Cancer-Based Criteria for Use in MainstreamBRCA1andBRCA2Genetic Testing in Patients With Breast CancerJAMA Network Open, 2019
- Moving into the mainstream: healthcare professionals’ views of implementing treatment focussed genetic testing in breast cancer careFamilial Cancer, 2019
- Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA MutationsJAMA Surgery, 2018
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trialThe Lancet Oncology, 2015